Longitudinal evaluation of anti-SARS-CoV-2 neutralizing antibody levels in 3-dose homologous (mRNA-1273- mRNA-1273- BNT162b2) vaccinated kidney transplant population: 18-month follow-up.

IJID Reg · 2025 · PMC12549382 · PMID 41143067

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A deeper analysis showed that 76.9% (10/13) of KTRs who were seropositive at TP5 showed increasing nAB levels compared to TP4 (95.7% [IQR: 88.7-96.3%]/1062 IU/mL [595-1896 IU/mL] vs 97.2% [IQR: 96.9-97.3%]/2363 IU/mL [1973-2829 IU/mL], Wilcoxon test, P = 0.0020), while 23% (3/13, seropositive at TP5) showed a decreasing trend without a significant difference in nAB levels (94% [IQR: 91.8-95%]/1095 IU/mL [544.6-2200 IU/mL] vs 82.4% [75.4- 83.2%]/292.6 IU/mL [150-570 IU/mL], Wilcoxon test, P = 0.2500).

also in 47,180 other papers

an increasing trendno p-value reported

This initial MAB did not exhibit a significant change after the first dose (TP1: 95.12%, IQR: 94.02-97.74% / 1424 IU/mL, SD factor: 2.66, MWU, P = 0.1649) or second dose at either TP2 (97.71%, IQR: 97.02-97.75%/ 2790 IU/mL, SD factor: 1.15, MWU, P = 0.1183) or TP3 (96.82%, IQR: 95.51-97.38%/ 2153 IU/mL, SD factor: 1.35, MWU, P = 0.0727), though an increasing trend was seen.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.